Suppressing somatostatin

Zucara Therapeutics Inc. is developing somatostatin receptor 2 antagonists to prevent hypoglycemia in Type I diabetes patients without decreasing the efficacy of insulin therapy.

In Type I diabetes, somatostatin production is elevated, leading to continuous inhibition of glucagon. Glucagon inhibition in turn prevents patients from increasing and normalizing blood glucose levels following insulin therapy. ...